Stockreport

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and Ig [Read more]